NYSE MKT
CVM

CEL-SCI Corp

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

CEL-SCI Corp Stock Price

Vitals

Today's Low:
$1.22
Today's High:
$1.27
Open Price:
$1.26
52W Low:
$1.86
52W High:
$5.42
Prev. Close:
$1.24
Volume:
125347

Company Statistics

Market Cap.:
$114.02 million
Book Value:
0.46
Revenue TTM:
$28558
Operating Margin TTM:
0%
Gross Profit TTM:
$-25355346
Profit Margin:
0%
Return on Assets TTM:
-40.9%
Return on Equity TTM:
-108.44%

Company Profile

CEL-SCI Corp had its IPO on 1987-01-01 under the ticker symbol CVM.

The company operates in the Healthcare sector and Biotechnology industry. CEL-SCI Corp has a staff strength of 0 employees.

Stock update

Shares of CEL-SCI Corp opened at $1.26 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.22 - $1.27, and closed at $1.23.

This is a -0.81% slip from the previous day's closing price.

A total volume of 125,347 shares were traded at the close of the day’s session.

In the last one week, shares of CEL-SCI Corp have slipped by -11.51%.

CEL-SCI Corp's Key Ratios

CEL-SCI Corp has a market cap of $114.02 million, indicating a price to book ratio of 2.6763 and a price to sales ratio of 11797.424.

In the last 12-months CEL-SCI Corp’s revenue was $28558 with a gross profit of $-25355346 and an EBITDA of $-29558648. The EBITDA ratio measures CEL-SCI Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CEL-SCI Corp’s operating margin was 0% while its return on assets stood at -40.9% with a return of equity of -108.44%.

In Q1, CEL-SCI Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 62.7%.

CEL-SCI Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.83 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CEL-SCI Corp’s profitability.

CEL-SCI Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.9179. Its price to sales ratio in the trailing 12-months stood at 11797.424.

CEL-SCI Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$38.20 million
Total Liabilities
$5.31 million
Operating Cash Flow
$-111452.00
Capital Expenditure
$111452
Dividend Payout Ratio
0%

CEL-SCI Corp ended 2024 with $38.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $38.20 million while shareholder equity stood at $20.15 million.

CEL-SCI Corp ended 2024 with $0 in deferred long-term liabilities, $5.31 million in other current liabilities, 437878.00 in common stock, $-471093411.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.05 million and cash and short-term investments were $10.05 million. The company’s total short-term debt was $1,849,749 while long-term debt stood at $0.

CEL-SCI Corp’s total current assets stands at $12.57 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.89 million and inventory worth $1.89 million.

In 2024, CEL-SCI Corp's operating cash flow was $-111452.00 while its capital expenditure stood at $111452.

Comparatively, CEL-SCI Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.23
52-Week High
$5.42
52-Week Low
$1.86
Analyst Target Price
$10.5

CEL-SCI Corp stock is currently trading at $1.23 per share. It touched a 52-week high of $5.42 and a 52-week low of $5.42. Analysts tracking the stock have a 12-month average target price of $10.5.

Its 50-day moving average was $1.69 and 200-day moving average was $2.3 The short ratio stood at 17.12 indicating a short percent outstanding of 0%.

Around 388.9% of the company’s stock are held by insiders while 1378.4% are held by institutions.

Frequently Asked Questions About CEL-SCI Corp

The stock symbol (also called stock or share ticker) of CEL-SCI Corp is CVM

The IPO of CEL-SCI Corp took place on 1987-01-01

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$92.55
-4.85
-4.98%
$0.25
-0
-1.16%
$10
0.31
+3.2%
U3O8 Corp (UWEFF)
$0.09
0
0%
$2493
-7.95
-0.32%
$109.1
-9.3
-7.85%
$64.09
-0.69
-1.07%
$15.29
-0.24
-1.55%
KDDL Limited (KDDL)
$1808
-66.1
-3.53%
$26.22
0.06
+0.23%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company’s lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Address

8229 Boone Boulevard, Vienna, VA, United States, 22182